Shanghai Kehua Bio-Engineering Secures Regulatory Approvals for Two New Diagnostic Kits

Stock News

Yesterday

Shanghai Kehua Bio-Engineering Co., Ltd. (SZSE: 002022) has announced that it, along with its controlled subsidiary Suzhou Tianlong Biotechnology Co., Ltd., has received medical device registration certificates for in vitro diagnostic reagents from China's National Medical Products Administration.

The newly certified products include a Chlamydia trachomatis nucleic acid detection kit (PCR-fluorescence method) and a Parainfluenza virus nucleic acid detection kit (fluorescence PCR method).

These registrations mark a significant expansion of the company's diagnostic product portfolio, allowing Shanghai Kehua Bio-Engineering to offer enhanced testing solutions for infectious diseases in clinical settings.

The approvals underscore the company's commitment to advancing molecular diagnostics and addressing growing public health needs for accurate and reliable pathogen detection.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/news/1178547175"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1178547175\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1178547175?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-15 19:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178547175","market":"sh","top_or_hot":-1,"title":"Shanghai Kehua Bio-Engineering Secures Regulatory Approvals for Two New Diagnostic Kits","media":"Stock News","content":"<p><b>Shanghai Kehua Bio-Engineering Co., Ltd.</b> (<b>SZSE: 002022</b>) has announced that it, along with its controlled subsidiary Suzhou Tianlong Biotechnology Co., Ltd., has received medical device registration certificates for in vitro diagnostic reagents from China's National Medical Products Administration.<br><br>The newly certified products include a <b>Chlamydia trachomatis nucleic acid detection kit (PCR-fluorescence method)</b> and a <b>Parainfluenza virus nucleic acid detection kit (fluorescence PCR method)</b>.<br><br>These registrations mark a significant expansion of the company's diagnostic product portfolio, allowing Shanghai Kehua Bio-Engineering to offer enhanced testing solutions for infectious diseases in clinical settings.<br><br>The approvals underscore the company's commitment to advancing molecular diagnostics and addressing growing public health needs for accurate and reliable pathogen detection.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Kehua Bio-Engineering Secures Regulatory Approvals for Two New Diagnostic Kits</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Kehua Bio-Engineering Secures Regulatory Approvals for Two New Diagnostic Kits\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-15 19:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Shanghai Kehua Bio-Engineering Co., Ltd.</b> (<b>SZSE: 002022</b>) has announced that it, along with its controlled subsidiary Suzhou Tianlong Biotechnology Co., Ltd., has received medical device registration certificates for in vitro diagnostic reagents from China's National Medical Products Administration.<br><br>The newly certified products include a <b>Chlamydia trachomatis nucleic acid detection kit (PCR-fluorescence method)</b> and a <b>Parainfluenza virus nucleic acid detection kit (fluorescence PCR method)</b>.<br><br>These registrations mark a significant expansion of the company's diagnostic product portfolio, allowing Shanghai Kehua Bio-Engineering to offer enhanced testing solutions for infectious diseases in clinical settings.<br><br>The approvals underscore the company's commitment to advancing molecular diagnostics and addressing growing public health needs for accurate and reliable pathogen detection.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HART","symbol_name":"NYLI Healthy Hearts ETF","start_time":0,"source_url":"","article_id":"1178547175","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178547175","pubTimestamp":1789471463,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Kehua Bio-Engineering Co., Ltd. (SZSE: 002022) has announced that it, along with its controlled subsidiary Suzhou Tianlong Biotechnology Co., Ltd., has received medical device registration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159883":"医疗器械","HART":"NYLI Healthy Hearts ETF","AGNG":"Global X Aging Population ETF","09996":"沛嘉医疗-B","BK0028":"国家队","002022":"科华生物","MEDX":"HORIZON KINETICS MEDICAL ETF","MDEV":"First Trust Indxx Medical Devices ETF","RSPH":"Invesco S&P 500 Equal Weight Health Care ETF","LGHT":"LANGAR GLOBAL HEALTHTECH ETF","BK1100":"医疗保健设备","LNGR":"Global X Longevity Thematic ETF","GDOC":"Goldman Sachs Future Health Care Equity ETF","BK1574":"生物医药B类股","BK1583":"高瓴概念","BK0239":"医药制造","PTH":"Invesco Dorsey Wright Healthcare Momentum ETF","BK0046":"生物疫苗","BK0188":"融资融券","IEIH":"iShares Evolved U.S. Innovative Healthcare ETF"},"translate_title":"上海科华生物工程两款新型诊断试剂盒获得监管部门批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159883":1,"LGHT":1,"AGNG":1,"RSPH":1,"09996":1,"002022":1,"GDOC":1,"IEIH":1,"HART":1,"MEDX":1,"LNGR":1,"MDEV":1,"PTH":1},"content_text":"Shanghai Kehua Bio-Engineering Co., Ltd. (SZSE: 002022) has announced that it, along with its controlled subsidiary Suzhou Tianlong Biotechnology Co., Ltd., has received medical device registration certificates for in vitro diagnostic reagents from China's National Medical Products Administration.The newly certified products include a Chlamydia trachomatis nucleic acid detection kit (PCR-fluorescence method) and a Parainfluenza virus nucleic acid detection kit (fluorescence PCR method).These registrations mark a significant expansion of the company's diagnostic product portfolio, allowing Shanghai Kehua Bio-Engineering to offer enhanced testing solutions for infectious diseases in clinical settings.The approvals underscore the company's commitment to advancing molecular diagnostics and addressing growing public health needs for accurate and reliable pathogen detection.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}